Novartis AG





Real-time Estimate Cboe Europe 07:27:56 2024-04-16 am EDT 5-day change 1st Jan Change
84.76 CHF -2.01% Intraday chart for Novartis AG -1.88% -0.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novartis reports positive interim results for Fabhalta CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients MT
Novartis Gets Priority Review for Kidney Disease Treatment DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) DJ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug MT
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares DJ
Novartis: licensing agreement in prostate cancer CF
Novartis: MorphoSys Board recommends tender offer CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins MT
Morphosys management bodies recommend acceptance of Novartis takeover bid DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer CI
Novartis begins tender offer for cancer-focused MorphoSys RE
NOVARTIS : UBS reiterates its recommendation on the stock CF
Novartis Launches Tender Offer for Germany's MorphoSys MT
Novartis initiates tender offer for MorphoSys CF
Novartis begins tender offer for cancer-focused MorphoSys RE
Dpa-AFX Overview: COMPANIES from 10.04.2024 - 15:15 DP
NOVARTIS AG : UBS remains its Buy rating ZD
Factbox-European companies cut jobs as economy sputters RE
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
94.7 USD
Average target price
107.5 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says